You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Claims for Patent: 5,354,760

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,354,760

Title:	Crystalline Tiagabine monohydrate, its preparation and use
Abstract:	The invention provides crystalline Tiagabine hydrochloride monohydrate, process for its preparation, compositions containing the same and its therapeutic use as anti-epileptic agent.
Inventor(s):	Petersen; Henning (Lyngby, DK), Nielsen; Peter (Herlev, DK), Cain; Michael (Grayslake, IL), Patel; Subhash (Chicago, IL)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	07/857,038
Patent Claims:	1. Crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having a differential scanning calorimetry profile with an onset from about 80.8.degree. C. to about 83.0.degree. C. 2. Crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate, having substantially the same X-ray diffractogram as set out in FIG. 1 and substantially the same IR spectrum, in KBr, as set out in FIG. 3. 3. A process for the preparation of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3enyl)nipecotic acid hydrochloride monohydrate, which process comprises forming an aqueous solution of R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride and crystallizing said R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate from solution by precipitation or recrystallization from water. 4. A process for the preparation of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate comprising acid catalyzed hydrolysis of the ethyl ester of R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride in an aqueous solution followed by crystallization of R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate from the aqueous solution by precipitation or recrystallization from water. 5. A pharmaceutical composition comprising an effective anti-epileptic amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having a differential scanning calorimetry profile with an onset from about 80.8.degree. C. to about 83.0.degree. C. together with a pharmaceutically acceptable carrier or diluent. 6. The pharmaceutical composition according to claim 5 in the form of an oral dosage unit containing from 1 to 200 mg of R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having a differential scanning calorimetry profile with an onset from about 80.8.degree. C. to about 83.0.degree. C. 7. A pharmaceutical composition comprising an effective anti-epileptic amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having substantially the same X-ray diffractogram as set out in FIG. 1 and substantially the same IR spectrum, in KBr, as set out in FIG. 3 together with a pharmaceutically acceptable carrier or diluent. 8. A method of treating epilepsy in a mammal comprising administering to the mammal an effective amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having a differential scanning calorimetry profile with an onset from about 80.8.degree. C. to about 83.0.degree. C. 9. A method of treating epilepsy in a mammal comprising administering to the mammal a pharmaceutical composition comprising an effective anti-epileptic amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having a differential scanning calorimetry profile with an onset from about 80.8.degree. C. to about 83.0.degree. C. together with a pharmaceutically acceptable carrier or diluent. 10. A method of treating epilepsy in a mammal comprising administering to the mammal an effective amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having substantially the same X-ray diffractogram as set out in FIG. 1 and substantially the same IR spectrum, in KBr, as set out in FIG. 3. 11. A method of treating epilepsy in a mammal comprising administering to the mammal a pharmaceutical composition comprising an effective anti-epileptic amount of crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate having substantially the same X-ray diffractogram as set out in FIG. 1 and substantially the same IR spectrum, in KBr, as set out in FIG. 3 together with a pharmaceutically acceptable carrier or diluent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.